IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia | MicrobiomeTrials← Back to trialsNCT03977493
IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2018-02-21Est. Completion: 2027-12-31
Enrollment target: 48 participants Locations- Inselspital - University Hospital Berne, Bern, Switzerland
- Centre hospitalier universitaire vaudois (CHUV), Lausanne, Switzerland
- Neurocentro della Svizzera Italiana, Lugano, Switzerland
- Neurocenter of St. Gallen, Sankt Gallen, Switzerland
- USZ- Univerity Hospital Zurich, Zurich, Switzerland
Other microbiome trials you might be interested in
Isolated Focal Hand Dystonia
This study aims to investigate the impact of accelerated transcranial magnetic stimulation (TMS) on brain function and b…
Durham, United StatesEst. completion Feb 5, 2027
Writer's CrampDystonias
Writer's cramps (WC) is a focal task-specific upper limb dystonia that significantly impairs handwriting and other manua…
Multiple LocationsEst. completion Dec 1, 2027
Dystonia
Focal Dystonia
Musician's Dystonia
Researchers want to test a procedure called deep brain simulation (DBS) to treat focal hand dystonia (FHD). A device cal…
Bethesda, United StatesEst. completion Feb 2, 2029